Vaccine Development and Manufacturing

GSK accelerates delivery timeline for US quadrivalent flu vaccine.

The European Medicines Agency reviews the safety of human papillomavirus vaccines.

The European Pharmacopoeia has incorporated new provisions to encourage the use of in-process quality control methods.

The divestment of Nimenrix and Mencevax was to satisfy regulatory clearances when GSK gained Novartis’ vaccines business in an asset swap in March 2015.

IDT Biologika acquired Aeras' vaccine manufacturing facility, and the companies will work together on tuberculosis vaccine development.

Medicago's new production facility will make plant-based vaccines and therapeutics.

A vaccine patch may eliminate the need for traditional means of vaccine distribution, according to an article in NPR.

GSK notifies CDC and FDA that it is recalling the remaining doses of its 2014–2015 flu vaccine, Flulaval Quadrivalent Thimerosal-free Pre-Filled Syringes, due to decreased potency.

GlaxoSmithKline announces global vaccines research and design facility to be based in Rockville, MD, USA.

NIH announced positive safety results from the vaccine, VSV-ZEBOV, and found that all patients in the study experienced a strong antibody response.

Second-generation needle-free injection systems will make parenteral drug administration more convenient, efficient, and safe.

Emergent BioSolutions announced FDA approval of Anthrasil, an inhalable treatment that targets Anthrax toxins, as well as a contract with BARDA to develop NuThrax, an anthrax vaccine candidate.

The agency will employ a ring vaccination method similar to the one used to eradicate smallpox.

Scientists and industry experts seek effective preventive therapies to combat global disease.

The pharmaceutical manufacturer pledged to freeze vaccine prices for Gavi-eligible countries for a decade.

Government and industry efforts to address manufacturing challenges move Ebola vaccine candidates into larger clinical trials.

Protein Sciences will evaluate sourcing Flublok from its Japanese licensee, UMN Pharma, which already runs a large-scale facility for the vaccine.

Baxter announced that it had entered into an agreement to sell its Vero cell technology and related assets to Nanotherapeutics.

US Department of Health and Human Services announced a declaration to provide immunity to legal claims made in the US in relation to three investigational Ebola vaccines.

Dalton Pharma Services announced it was awarded funding from ISTPCanada for its project to develop vaccines for respiratory syncytial virus and parainfluenza type 3.

The United States government is ramping up support for formulation, production, and packaging of Ebola treatments.

The agency recommends that companies developing drugs to treat Ebola apply for orphan drug designation.

Prefilled syringes offer advantages to manufacturers, healthcare professionals, and patients.

Demand for new therapies and vaccines spotlights production challenges.

Partnership is awarded for licensing of low-cost vaccine for the treatment of bacterial meningitis.